Erythematotelangiectatic Rosacea Clinical Trial
Official title:
Feasibility Study: Evaluation of the Effectiveness and Safety of the Ulthera® System for Treatment of Erythematotelangiectatic Rosacea
Up to 12 subjects will be enrolled. Enrolled subjects will receive one or two Ultherapy treatments on the cheeks, depending on their assigned study group. Follow-up visits will occur 14, 30 and 90 days post-treatment. Study images will be obtained pre-treatment, 30-60 min post-treatment, and at each follow-up visit.
This study is a prospective, randomized, single-center clinical trial. The study will be conducted in two Phases. In Phase I, subjects will be assigned to one of two treatment groups. One study group will receive one dual depth Ultherapy treatment to a region on the cheeks, and one study group will receive two dual depth Ultherapy treatments to a region on the cheeks 14 days apart. Average pain scores will be obtained using a Numeric Rating Scale following each region of treatment and for each depth of treatment. In Phase II, based on observations of last follow-up visit in Phase I (at 90 days after treatment), subjects will be given the option to receive treatment of the affected area(s) for the protocol specified region, treated at the treatment depth showing the most efficacy in Phase I. Efficacy will be determined by improvement in Erythematotelangiectatic Rosacea in the treatment area versus control (an untreated area) as determined by primary investigator assessment at the last follow-up visit in Phase I. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03708263 -
Evaluation of the New Laser PHOTOLASE PLV-585nm for the Treatment of Rosacea
|
N/A | |
Completed |
NCT02268474 -
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
|
N/A | |
Completed |
NCT00989014 -
Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea
|
Phase 2 | |
Completed |
NCT06331533 -
Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea
|
Phase 4 | |
Completed |
NCT02144181 -
Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea
|
N/A | |
Recruiting |
NCT05360251 -
Pulsed Dye Laser and Intense Pulsed Light Configured With Different Wavelength Bands in Improving Erythematotelangiectatic Rosacea
|
N/A | |
Completed |
NCT01045551 -
Open Label Pilot Study of Apremilast in Treatment of Rosacea
|
Phase 2 | |
Completed |
NCT00945373 -
Combination Therapy for the Treatment of Rosacea
|
Phase 1 | |
Completed |
NCT04153188 -
Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea
|
Phase 4 | |
Completed |
NCT02393937 -
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
|
Phase 3 | |
Completed |
NCT02052999 -
Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients
|
Phase 2 |